The European Commission has cleared the proposed acquisition by AstraZeneca of US-based biopharmaceutical company Alexion Pharmaceuticals for approximately $39bn or $175 a share.
This development comes after competition clearances in the US, Japan and other countries worldwide.
Go deeper with GlobalData
Regulatory clearance is still pending in the UK and is needed to conclude the acquisition.
In May, the UK Competition and Markets Authority (CMA) launched an investigation into the proposed acquisition.
The CMA is reviewing whether the deal will cause a relevant merger situation and if the creation of that situation would lower competition within any market or in the UK goods or services markets.
AstraZeneca executive director and chief financial officer Marc Dunoyer said: “We are pleased to have secured clearance from the European Commission for the proposed acquisition of Alexion, a pioneer in the discovery and development of medicines for rare diseases.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines.”
In December last year, AstraZeneca proposed the deal in a bid to boost its scientific footprint in immunology by leveraging Alexion’s complement-technology platform and broad pipeline.
Alexion develops therapies for immune-mediated rare diseases caused by uncontrolled activation of the complement system, a critical part of the immune system.
Rare diseases signify a high-growth area with substantial unmet medical needs, AstraZeneca noted.
More than 7,000 rare diseases are currently identified but only about 5% have the US Food and Drug Administration-approved (FDA) therapies.
According to estimates, future demand for rare diseases medicines could increase by a low double-digit percentage.
The acquisition of Alexion secured the support of both parties’ shareholders in May and is slated to conclude in the third quarter of this year.
After closing, a rare disease-focused group known as ‘Alexion, The AstraZeneca Rare Disease Unit’ will be formed.
